Skip to content
AUDIO JOURNAL OF ONCOLOGY—PARP-Inhibition Beyond Initial Therapy Extends Life with Advanced Ovarian Cancer

AUDIO JOURNAL OF ONCOLOGY—PARP-Inhibition Beyond Initial Therapy Extends Life with Advanced Ovarian Cancer

Get the podcast

PARIS, France—Long remissions and potential cures were reported at the 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) in patients with newly diagnosed advanced ovarian cancer

The Audio Journal of Oncology

PARIS, France—Long remissions and potential cures were reported at the 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) in patients with newly diagnosed advanced ovarian cancers expressing the BRCA mutation who were treated with the poly ADP ribose polymerase (PARP) inhibitor olaparib after initial therapy.

Two thirds of women were alive seven years later in the phase three SOLO1 trial of olaparib maintenance therapy compared with placebo. The lead author of the study, Paul DiSilvestro MD, Professor in the Department of Obstetrics & Gynecology and Director of the Program of Women’s Oncology at Women & Infants Hospital, Brown University in Providence Rhode Island, gives the details to the Audio Journal of Oncology’s Peter Goodwin.

Next in ESMO 2022

All 4 interviews

Interview 4 of 4

PM 2.5Evidence Links Particulate Air Pollution to Non-Small Cell Lung Cancer

PM 2.5Evidence Links Particulate Air Pollution to Non-Small Cell Lung Cancer

Audio Journal of Oncology September 9, 2022 By Peter M Goodwin PARIS, France—Particulate air pollution was identified as a key step in malignant transformation from benign DNA to non-small cell lung c

4 October 2022

Related Episodes

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer

MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after first line chemo-immunotherapy induction. Results from the phase 3 DeLLphi-305 trial were reported at the 2026 Annual Congress of the European Society for Medical Oncology showing significantly improved overall and progression-free survival. Peter Goodwin spoke with study author Jacob Sands MD, Associate Chief of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in Boston, USA, and Assistant Professor of Medicine at Harvard Medical School:

12 Nov 2026
4 min
Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer

Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer

MADRID, Spain—The antibody-drug conjugate datopotamab deruxtecan (aTrop-2-directed antibody carrying a topoisomerase inhibitor payload) achieved clinically meaningful intracranial responses among patients with resected inoperable or metastatic triple negative breast cancer with CNS involvement in the TROPION-Breast02 study discussed at the 2026 Annual Meeting of the European Society for Medical Oncology. Peter Goodwin heard the details from the study’s first author: Rebecca Dent MD, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre in Singapore.

5 Nov 2026
10 min
James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies

James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies

MADRID, Spain— Personalized mRNA cancer vaccines for a range of tumor types are now seen as a realistic possibility thanks to mRNA technology already harnessed for treating melanoma in the phase III INTerpath-001 trial reported at the 2026 Annual Congress of the European Society for Medical Oncology. Peter Goodwin heard the latest on the potential of cancer vaccines from Scientific Co-Chair of ESMO 2026, James Larkin PhD FRCP F Med Sci, Head of The Royal Marsden Skin Unit, and Joint Training Programme Director for Medical Oncology and Lead of the Cancer Immunotherapy Theme at The Royal Marsden’s Institute of Cancer Research NIHR Biomedical Research Centre, in London UK.

2 Nov 2026
15 min